Loading company…
VivaVision Biotech develops drugs for ophthalmic and dermal inflammatory diseases.
Founded in 2016 and based in Shanghai, VivaVision Biotech develops treatments for ophthalmic and dermal inflammatory diseases, with an additional branch in Jiaxing. Its pipeline includes VVN001 for dry eye, VVN460 for plaque psoriasis and VVN539 for glaucoma. Clinical testing has taken place in the US and China since 2020. In July 2025, the company raised CNY 140 million in Series D2+ funding from Hunan Energy Investment Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in